Novabridge Reveals Promising Ragistomig Phase 1 Data at ESMO
In a Phase 1 expansion of ragistomig, a 4-1BB × PD-L1 bispecific, the 3 mg/kg every-six-weeks regimen delivered an...
Aardvark’s HERO Trial for Prader-Willi Doses First Patient
Enrollment remains on pace for a Q3 2026 topline readout in Aardvark Therapeutics’ Phase 3 HERO trial of ARD-101...
Promising Results for Samuraciclib in Advanced Breast Cancer
Samuraciclib plus fulvestrant delivered an overall response rate of 55% and a median progression-free survival of 14.5 months in...
Nucana Data Shows NUC-7738 Activity in Resistant Melanoma
In PD-1 inhibitor–resistant metastatic melanoma, NuCana’s NUC-7738 plus pembrolizumab produced two partial responses (one confirmed) and seven instances of...
Barinthus Bio Phase 1 Avalon Celiac Trial Update
In the single-ascending dose portion of the first-in-human AVALON trial (NCT06310291), VTP-1000 was well tolerated with no treatment-related serious...
ICH E6(R3) Sparks Urgency, But Real Change Has Barely Begun
The 2025 Veeva Clinical Operations Oversight Forum in Copenhagen brought together sponsors, CROs, and technology partners to examine one...
What Happened to Accendatech’s Promising IPF Drug Trial?
Accendatech reported that in an exploratory cohort of idiopathic pulmonary fibrosis, 38% of evaluable patients (11 of 29) on...
20+ Orelabrutinib Studies Presented at ASH Annual Meeting
Post-cycle 6 in newly diagnosed primary CNS lymphoma treated with orelabrutinib, rituximab, and high-dose methotrexate, objective responses reached 89.5%...
Medicenna Reveals New MDNA11 Clinical Data in Live Webinar
Medicenna will unveil updated ABILITY-1 Phase 1/2 data for its long-acting IL-2 superkine MDNA11—both as monotherapy and in combination...
Praxis & FDA Align on Accelerated Pathway for SCN2A Drug
Praxis secured FDA agreement to convert EMBRAVE3, its registrational study of elsunersen in early-onset SCN2A developmental and epileptic encephalopathy,...
